Implant Sciences' Desktop Trace Detector Purchased by Asian Postal Service for Explosives & Drugs Screening
WILMINGTON, MA, Feb 05, 2013 (MARKETWIRE via COMTEX) --
Implant Sciences Corporation (OTCQB: IMSC), a high technology
supplier of systems and sensors for homeland security and defense
markets, today announced it had received an order for its Quantum
Sniffer(TM) QS-B220 desktop explosives and drugs trace detector from
the national postal service of an Asian nation. The QS-B220 will be
used to inspect mail for explosives and drugs. This sale was made
through Implant Sciences' distributor Global Pro Security, an
internationally recognized wholesale distributor of security and
"Postal services around the world are faced with the challenge of
guarding against illicit drug trafficking and explosives hidden in
shipments. With the deployment of the QS-B220 for this function, we
are pleased to announce that we have successfully penetrated yet
another market segment with our versatile product," stated Implant
Sciences' President and CEO, Glenn D. Bolduc.
"Our QS-B220 and QS-H150 have performed extremely well in some key,
high-volume airports in screening parcels of all sizes. This postal
service customer became aware of our Quantum Sniffers' reputation for
high performance, fast clear-down time between screens, and low
maintenance costs. This led to their decision to purchase the QS-B220
over competing offerings," added Implant Sciences' Vice President of
Sales and Marketing, Dr. Darryl Jones.
About Quantum Sniffer(TM) QS-B220 Desktop Explosives & Drugs Trace
The Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to
rapidly detect and identify trace amounts of a wide variety of
military, commercial, and homemade explosives, as well as drugs.
Featuring a radioactive material-free design, push-button maintenance
and diagnostics, and internal automatic self-calibration, the QS-B220
brings new levels of performance and convenience to desktop trace
detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences develops, manufactures and sells sophisticated
sensors and systems for Security, Safety, and Defense (SS&D) markets.
The Company has developed proprietary technologies used in its
commercial explosive and narcotics trace detection systems which ship
to a growing number of locations domestically and internationally.
Implant Sciences' QS-H150 handheld explosives trace detector has
received Qualified Anti-Terrorism Technology Designation and the
Company's QS-B220 desktop explosives and drugs trace detector has
received a Developmental Testing & Evaluation (DT&E) Designation by
the U.S. Department of Homeland Security under the Support
Anti-terrorism by Fostering Effective Technology Act of 2002 (the
SAFETY Act). For further details on the Company and its products,
please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements,"
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Such statements are based on management's current
expectations and are subject to risks and uncertainties that could
cause the Company's actual results to differ materially from the
forward-looking statements. Such risks and uncertainties include, but
are not limited to, the risks that our explosives detection products
and technologies (including any new products we may develop) may not
be accepted by the Transportation Security Administration or by other
U.S. or foreign government and law enforcement agencies or commercial
consumers of security products; economic, political and other risks
associated with international sales and operations could adversely
affect our sales; our business is subject to intense competition and
rapid technological change; the risks that our markets are subject to
technological change and that our success depends on our ability to
develop and introduce new products; and other risks and uncertainties
described in our filings with the Securities and Exchange Commission,
including its most recent Forms 10-K, 10-Q and 8-K. Such statements
are based on management's current expectations and assumptions which
could differ materially from the forward-looking statements.
Implant Sciences Corporation
SOURCE: Implant Sciences Corporation
[ Back To TMCnet.com's Homepage ]